SLC7A10 and schizophrenia: As a result, inhibitors targeting Asc-1 could decrease the tonic release of D-Ser and impair NMDAR function, providing therapeutic benefits for schizophrenia at concentrations that do not affect its role in inhibitory neurons24–26.